{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T21:26:16Z","timestamp":1784582776455,"version":"3.55.0"},"reference-count":21,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2003,5,19]],"date-time":"2003-05-19T00:00:00Z","timestamp":1053302400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2003,6]]},"abstract":"<jats:title>Abstract:<\/jats:title><jats:p>Approximately 45% of newly diagnosed patients with essential thrombocythaemia (ET) demonstrate subnormal plasma erythropoietin (EPO) concentrations, which constitutes a risk factor for occlusive vascular events. In 58 ET patients, a possible association between polycythaemia rubra vera\u20101 (PRV\u20101) overexpression and subnormal plasma EPO was investigated, which was always measured prior to the institution of platelet lowering agents. At the time when PRV\u20101 expression was measured, 28 of 58 (48%) ET patients had received platelet lowering treatment. PRV\u20101 expression was measured by quantitative real\u2010time reverse transcription\u2013polymerase chain reaction assay of mRNA extracted from purified peripheral blood buffy coat. The cycle threshold (CT) value of PRV\u20101 was determined and was divided with the CT value for the housekeeping GAPDH gene transcript. A quotient &lt;0.93 was defined as PRV\u20101 positive. Of the ET patients 12 of 58 (21%) were PRV\u20101 positive and 19 of 58 (33%) demonstrated subnormal plasma EPO. In the 58 ET patients there was a significant association between low plasma EPO and PRV\u20101 positive results (<jats:italic>P<\/jats:italic>\u2003=\u20030.001). The 30 ET patients who had not received any platelet lowering treatment showed a significant (<jats:italic>P<\/jats:italic>\u2003=\u20030.005) relation between PRV\u20101 positivity and subnormal plasma EPO. No such relationship was present in the 28 ET patients who had received prior treatment with the above drugs (<jats:italic>P<\/jats:italic>\u2003=\u20030.147).<\/jats:p>","DOI":"10.1034\/j.1600-0609.2003.00079.x","type":"journal-article","created":{"date-parts":[[2003,5,19]],"date-time":"2003-05-19T14:23:45Z","timestamp":1053354225000},"page":"358-362","source":"Crossref","is-referenced-by-count":14,"title":["The presence of a significant association between elevated PRV\u20101 mRNA expression and low plasma erythropoietin concentration in essential thrombocythaemia"],"prefix":"10.1034","volume":"70","author":[{"given":"Peter","family":"Johansson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Andr\u00e9asson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soodabeh","family":"Safai\u2010Kutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lovisa","family":"Wennstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Palmqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Ricksten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6ran","family":"Lindstedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Kutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2003,5,19]]},"reference":[{"key":"e_1_2_11_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(84)90750-2"},{"key":"e_1_2_11_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198607313150503"},{"key":"e_1_2_11_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1992.tb02999.x"},{"key":"e_1_2_11_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2257.1995.tb01239.x"},{"key":"e_1_2_11_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1998.tb01040.x"},{"key":"e_1_2_11_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03386.x"},{"key":"e_1_2_11_8_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428190009057645"},{"key":"e_1_2_11_9_2","doi-asserted-by":"publisher","DOI":"10.1159\/000063064"},{"key":"e_1_2_11_10_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428190009060324"},{"key":"e_1_2_11_11_2","first-page":"423","article-title":"Plasma erythropoietin in essential thrombocythaemia","volume":"35","author":"Viala JJ","year":"1993","journal-title":"Nouv Rev Fr Hematol"},{"key":"e_1_2_11_12_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428190009148401"},{"key":"e_1_2_11_13_2","volume-title":"Clinical and Experimental Studies in Polycythemia Vera and Essential Thrombocythemia (Dissertation)","author":"Andr\u00e9asson B.","year":"2000"},{"key":"e_1_2_11_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V93.2.417"},{"key":"e_1_2_11_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-472X(01)00640-3"},{"key":"e_1_2_11_16_2","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1182\/blood.V100.5.1596.h81702001596_1596_1601","article-title":"Predictive values of X\u2010chromosome inactivation patterns and clinicohematologic parameters for vascular complications in female patients with essential thrombocythemia","volume":"100","author":"Shih LY","year":"2002","journal-title":"Blood"},{"key":"e_1_2_11_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-06-1909"},{"key":"e_1_2_11_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.8.2569"},{"key":"e_1_2_11_19_2","first-page":"29","article-title":"Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment","volume":"34","author":"Murphy S","year":"1997","journal-title":"Semin Hematol"},{"key":"e_1_2_11_20_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199609074359"},{"key":"e_1_2_11_21_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365519850186247"},{"key":"e_1_2_11_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.507"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1600-0609.2003.00079.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1600-0609.2003.00079.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1034\/j.1600-0609.2003.00079.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T16:44:30Z","timestamp":1697215470000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1034\/j.1600-0609.2003.00079.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,5,19]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2003,6]]}},"alternative-id":["10.1034\/j.1600-0609.2003.00079.x"],"URL":"https:\/\/doi.org\/10.1034\/j.1600-0609.2003.00079.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,5,19]]}}}